|Bid||11.25 x 200|
|Ask||11.60 x 500|
|Day's Range||11.05 - 11.50|
|52 Week Range||5.42 - 25.95|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
While Zynerba's share price is still roughly half of last year's peak, the company has gotten attention from Wall Street with big upside in analyst calls in recent days.
Experts expect a serious cannabis shortage as Canada looks to legalize recreational cannabis in 2018, creating huge opportunities for savvy investors
For investors, increase in profitability and industry-beating performance can be essential considerations in an investment. Below, I will examine Zynerba Pharmaceuticals Inc’s (NASDAQ:ZYNE) track record on a high level, toRead More...
Shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE ), a specialty pharmaceutical company that focuses on developing and commercializing pharmaceutically produced transdermal cannabinoid treatments, traded ...
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), a pharmaceuticals company based in United States, received a lot of attention from a substantial price increase on the NasdaqGM in the over the last fewRead More...
On a per-share basis, the Devon, Pennsylvania-based company said it had a loss of 63 cents. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
The Street reacted to Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE )’s positive Fragile X trial results with marked ambivalence. Investors propelled the stock 76 percent higher even as biotech and behavioral ...
Microchip Technology, United Continental and Zynerba Pharmaceuticals highlighted as Zacks Bull and Bear of the Day
On Thursday, shares of clinical-stage specialty pharmaceutical company Zynerba Pharmaceuticals (ZYNE) are soaring, up nearly 54% in afternoon trading after it announced positive results in a mid-stage study of its cannabis-derived gel treatment.
Zynerba Pharmaceuticals shares saw a huge gain early on Thursday after the firm announced positive results from its mid-stage cannabinoid trial.
While most pot stocks have at least doubled in value over the past 12 months, these two are down nearly 40%!
The month of August has been hard one for cannabis drug stocks. After Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE ) reported a pair of disappointing trial results in its Phase 2 STAR 1 and STOP trials, respectively, ...
This clinical-stage cannabinoid-based drug developer has a long way to go to prove its worth to investors.
Zynerba Pharmaceuticals saw its shares sink to a 52-week low after the firm announced results from its midstage trial evaluating cannabidiol gel for the treatment of knee pain due to osteoarthritis.